Group structure and shareholders
Corporate structure as of December 31, 2024
In the financial year 2024, the company’s head office was located at Seestrasse 16, 8700 Küsnacht, Switzerland. As of January 1, 2025, the head office will be relocated to Theaterstrasse 12, 8001 Zurich, Switzerland.
Scope of consolidation
Bellevue Group AG is the only listed company within the Group. The investment companies we manage, BB Biotech AG and Bellevue Healthcare Trust plc, are independent companies listed on their respective stock exchanges. The companies consolidated by Bellevue Group are listed, together with information regarding their domicile and share capital and the interest held by the Group, in the notes to the consolidated financial statements, note 6 «Major subsidiaries».
Major shareholders
Based on the notifications received and published by Bellevue Group AG, the following parties hold significant voting rights:
Shareholder or beneficial owner | 31.12.2024 Voting rights held | 31.12.2024 Number of shares held | 31.12.2023 Voting rights held | 31.12.2023 Number of shares held | ||||
Martin Bisang, Küsnacht | 23.91% | 3 218 400 | 20.43% | 2 750 000 | ||||
Hansjörg Wyss, Cambridge MA (USA) | 9.66% | 1 300 000 | 9.66% | 1 300 000 | ||||
Jürg und Manuela Schäppi, Rapperswil-Jona | 9.18% | 1 235 299 | 9.05% | 1 217 799 |
The shareholders Martin Bisang (Küsnacht), as well as Jürg and Manuela Schäppi (Rapperswil-Jona) signed a shareholder agreement on October 25, 2018. The Group was represented by Martin Bisang and controlled 29.48% of the voting rights as at December 31, 2023. The group was terminated on February 20, 2024.
Disclosure notifications are retrievable from the SIX Swiss Exchange website at: https://www.ser-ag.com/en/resources/notifications-market-participants/significant-shareholders.html#/
Cross-shareholdings
There are no cross-shareholdings between Bellevue Group AG or its subsidiaries and other corporations.